Bausch Health Companies Inc. (NYSE:BHC) is one of the 15 best NYSE penny stocks to buy according to hedge funds.
On July 6, Bausch Health Companies Inc.’s (NYSE:BHC) subsidiary, Bausch Health Canada, shared the listing of PrOKEDI’s 75mg and 100mg dosages in the Régie de l’assurance maladie du Québec (RAMQ) formulary
PrOKEDI is an injectable suspension of risperidone that is used to treat adults with schizophrenia. It attains clinically meaningful concentrations of the active compound in the initial several hours after injection, without the need for oral supplementation or a loading dose. It also offers prolonged drug release throughout a four-week dosing interval.
According to Bausch Health, this decision by the company signifies a major milestone in obtaining reimbursement for PrOKEDI in Quebec. The company noted that it will maintain its efforts with other provincial jurisdictions consistent with their respective coverage processes. Back on June 9, Bausch Health Canada disclosed that it had completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA), which led to a Letter of Intent for PrOKEDI’s 100mg and 75mg dosages.